Navigation Links
Powerful gene-editing tool appears to cause off-target mutations in human cells
Date:6/23/2013

In the past year a group of synthetic proteins called CRISPR-Cas RNA-guided nucleases (RGNs) have generated great excitement in the scientific community as gene-editing tools. Exploiting a method that some bacteria use to combat viruses and other pathogens, CRISPR-Cas RGNs can cut through DNA strands at specific sites, allowing the insertion of new genetic material. However, a team of Massachusetts General Hospital (MGH) researchers has found a significant limitation to the use of CRISPR-Cas RGNs, production of unwanted DNA mutations at sites other than the desired target.

"We found that expression of CRISPR-Cas RGNs in human cells can have off-target effects that, surprisingly, can occur at sites with significant sequence differences from the targeted DNA site," says J. Keith Joung, MD, PhD, associate chief for Research in the Massachusetts General Hospital (MGH) Department of Pathology and co-senior author of the report receiving online publication in Nature Biotechnology. "RGNs continue to have tremendous advantages over other genome editing technologies, but these findings have now focused our work on improving their precision."

Consisting of a DNA-cutting enzyme called Cas 9, coupled with a short, 20-nucleotide segment of RNA that matches the target DNA segment, CRISPR-Cas RGNs mimic the primitive immune systems of certain bacteria. When these microbes are infected by viruses or other organisms, they copy a segment of the invader's genetic code and incorporate it into their DNA, passing it on to future bacterial generations. If the same pathogen is encountered in the future, the bacterial enzyme called Cas9, guided by an RNA sequence the matches the copied DNA segment, inactivates the pathogen by cutting its DNA at the target site.

About a year ago, scientists reported the first use of programmed CRISPR-Cas RGNs to target and cut specific DNA sites. Since then several research teams, including Joung's, have succesf
'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. UMass Amherst researchers develop powerful new technique to study protein function
2. Inspiring teens with research virus: Expert-mentored bioscience contest proves a powerful vector
3. A dual look at photosystem II using the worlds most powerful X-ray laser
4. Powerful enzymes create ethanol from agricultural harvest waste
5. Black piranha, megapiranha have most powerful bites of fish living or extinct, finds GW researcher
6. UF researcher tests powerful new tool to advance ecology, conservation
7. Team solves birth and migration mysteries of cortexs powerful inhibitors, chandelier cells
8. Powerful tool to fight wildlife crime unveiled
9. Black belts white matter shows how a powerful punch comes from the brain
10. Powerful class of antioxidants may be potent Parkinsons treatment
11. UTMB researchers create powerful new method to analyze genetic data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... challenged conventional thinking on how the bowel lining develops ... how bowel cancer starts. , The researchers produced evidence ... the ,crypts, that are a feature of the bowel ... bowel cancer development, a controversial finding as scientists are ... 3D imaging technologies, Dr Chin Wee Tan and Professor ...
(Date:10/16/2014)... Syncytial Virus causes severe respiratory tract infections and ... year. Scientists at VIB and Ghent University have ... counteract this common virus infection. , Xavier ... that paves the way for the development of ... virus that causes suffering in numerous small children ...
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... leading edge technologies including Wocket™, the Smart Wallet, at ... Conferenece. FiRe is a leading global conference on the ... Hosted by Mark Anderson , founder and publisher ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... In recent years, the possible applications for double-walled ... those working on developing renewable energy technologies. These ... thin enough to be transparent, yet can still ... advanced solar panels, sensors and a host of ...
... for Glycomics in collaboration with colleagues at the ... to identifying a broad spectrum treatment for the ... These highly-infectious viruses are the leading cause of ... of hospitalisations in the developed world, and hundreds ...
... Dec. 23, 2008 -- The reproductive spores of many ... to new research by mycologists and applied mathematicians at ... this week in the Proceedings of the National ... fungal spores is within one percent of the absolute ...
Cached Biology News:Researchers find chink in the armor of viral 'tummy bug' 2In many fungi, reproductive spores are remarkably aerodynamic 2
(Date:10/25/2014)... Charlotte, NC (PRWEB) October 24, 2014 ... high intensity focused ultrasound (HIFU) technology, announced that ... Carol, M.D. as Chief Executive Officer, President and ... new role Dr. Carol will take-on expanded responsibilities ... HIFU technology, as well as overseeing commercialization, manufacturing ...
(Date:10/25/2014)... JERUSALEM , October 24, 2014 ... a clinical-stage pharmaceutical company focused on the development of ... CEO, Nadav Kidron will present at FireRock ... ,FireRock Capital,s Annual Micro-Cap Conference ,Date: Tuesday, October 28, ... Building, New York City , ...
(Date:10/25/2014)... 2014 Investor-Edge has initiated coverage ... CYTR ), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ... Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM ), and ... companies can be accessed at: http://investor-edge.com/register . ... ended on a positive note as the Dow Jones ...
(Date:10/22/2014)... 22, 2014 New test innovations will be ... diagnostic (IVD) test industry, especially as companies struggle with ... listed more than 25 testing innovations in important disease ... of IVD products. Kalorama details the new approaches its biennial ... for In Vitro Diagnostic Tests , 9th Edition ...
Breaking Biology Technology:SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3
... Inc. (Nasdaq:,BIOD) today reported financial results for its second quarter ... $9.6 million or $0.43 per share., "We remain on ... and Chairman of Biodel. "The last patient visits for,both pivotal ... We,expect to announce top line data late in the third ...
... Pennsylvania and OXFORD, England, May 9 ,EUSA Pharma ... oncology, pain control and critical care, today announced ... following the,approval of Cytogen,s shareholders at a special ... of the acquisition agreement, Cytogen shareholders will,receive $0.62 ...
... Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced today that the ... 2008 Healthcare Conference on May 14, 2008 at 5:20 ... Seasons Hotel in Las,Vegas, Nevada. Dominic P. Behan, Ph.D., ... to provide an overview of the,company, including its clinical ...
Cached Biology Technology:Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 2Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 3Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 4Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 5Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 6Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 7Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 8Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 9EUSA Pharma Completes Acquisition Of Cytogen Corporation 2EUSA Pharma Completes Acquisition Of Cytogen Corporation 3Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference 2Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference 3
normal human fibroblasts Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
3T3 cells (RSV-transformed) Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
PC12 (rat phaeochromocytoma) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Peptide-affinity Purified Polyclonal Antibody to Olfactory Receptor, Family 2, Subfamily H, Member 3...
Biology Products: